[go: up one dir, main page]

MX2017009694A - Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders. - Google Patents

Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders.

Info

Publication number
MX2017009694A
MX2017009694A MX2017009694A MX2017009694A MX2017009694A MX 2017009694 A MX2017009694 A MX 2017009694A MX 2017009694 A MX2017009694 A MX 2017009694A MX 2017009694 A MX2017009694 A MX 2017009694A MX 2017009694 A MX2017009694 A MX 2017009694A
Authority
MX
Mexico
Prior art keywords
cd40l
methods
disorders
treating
related diseases
Prior art date
Application number
MX2017009694A
Other languages
Spanish (es)
Other versions
MX392480B (en
Inventor
M Lincecum John
Jiang Bingbing
N Perrin Steven
Gill Alan
G Vieira Fernando
A Gill Cynthia
Original Assignee
Als Therapy Development Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Development Inst filed Critical Als Therapy Development Inst
Publication of MX2017009694A publication Critical patent/MX2017009694A/en
Publication of MX392480B publication Critical patent/MX392480B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)

Abstract

Anticuerpos anti-CD40L humana genomanipulados para no contar con la capacidad de activar plaquetas y métodos para tratar a pacientes que tienen una enfermedad asociada a CD40L humana.Genomanipulated human anti-CD40L antibodies to not have the ability to activate platelets and methods to treat patients who have a disease associated with human CD40L.

MX2017009694A 2015-02-03 2016-02-02 ANTI-CLUSHER OF DIFFERENTIATION 40 LIGAND (CD40L) ANTIBODIES AND METHODS FOR TREATING DISEASES OR DISORDERS RELATED TO CLUSHER OF DIFFERENTIATION 40 LIGAND (CD40L). MX392480B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562111261P 2015-02-03 2015-02-03
PCT/US2016/016165 WO2016126702A1 (en) 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Publications (2)

Publication Number Publication Date
MX2017009694A true MX2017009694A (en) 2018-03-15
MX392480B MX392480B (en) 2025-03-24

Family

ID=56564599

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009694A MX392480B (en) 2015-02-03 2016-02-02 ANTI-CLUSHER OF DIFFERENTIATION 40 LIGAND (CD40L) ANTIBODIES AND METHODS FOR TREATING DISEASES OR DISORDERS RELATED TO CLUSHER OF DIFFERENTIATION 40 LIGAND (CD40L).
MX2022005655A MX2022005655A (en) 2015-02-03 2017-07-26 ANTI-CUMULUS DIFFERENTIATION LIGAND 40 (CD40L) ANTIBODIES AND METHODS FOR TREATING DISEASES OR DISORDERS RELATED TO CUMULUS DIFFERENTIATION LIGAND 40 (CD40L).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005655A MX2022005655A (en) 2015-02-03 2017-07-26 ANTI-CUMULUS DIFFERENTIATION LIGAND 40 (CD40L) ANTIBODIES AND METHODS FOR TREATING DISEASES OR DISORDERS RELATED TO CUMULUS DIFFERENTIATION LIGAND 40 (CD40L).

Country Status (15)

Country Link
US (6) US10106618B2 (en)
EP (2) EP3253412B1 (en)
JP (4) JP6797810B2 (en)
KR (2) KR20250007045A (en)
CN (2) CN114195895B (en)
AU (3) AU2016215505B8 (en)
CA (1) CA2974135A1 (en)
DK (1) DK3253412T3 (en)
GB (1) GB2552429A (en)
IL (3) IL322241A (en)
MA (1) MA41459A (en)
MX (2) MX392480B (en)
RU (1) RU2727646C2 (en)
SG (2) SG11201706258WA (en)
WO (1) WO2016126702A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3556774T3 (en) 2011-03-11 2024-07-01 Beth Israel Deaconess Medical Center Inc. Anti-cd40 antibodies and uses thereof
MA41459A (en) * 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
KR20250007054A (en) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. Humanized anti-cd40 antibodies and uses thereof
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
EP4491193A3 (en) * 2019-07-01 2025-04-30 Tonix Pharma Limited Anti-cd154 antibodies and uses thereof
JP2022540187A (en) * 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド Novel fusion protein and use thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
MX2023008055A (en) * 2021-01-06 2023-08-22 Tonix Pharma Ltd Methods of inducing immune tolerance with modified anti-cd154 antibodies.
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN114149508B (en) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 Fusion protein combined with CD40L and application thereof
KR20230108156A (en) * 2022-01-10 2023-07-18 주식회사 금호에이치티 Antibody specifically binding to CD40L and use thereof
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2025117849A1 (en) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
IL110855A (en) 1993-09-02 1999-04-11 Dartmouth College Methods for inducing antigen-specific t cell tolerance
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EA200501076A1 (en) 1997-01-10 2006-06-30 Байоджен Айдек Ма Инк. TREATMENT OF VARIETY JADE WITH THE USE OF ANTI-CD40L COMPOUNDS
AU735592B2 (en) 1997-05-17 2001-07-12 Biogen Idec Ma Inc. Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
HUP0101689A3 (en) 1998-04-03 2004-08-30 Trustees Of Darmouth College H Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP2003513937A (en) 1999-11-08 2003-04-15 アイデック・ファーマシューティカルズ・コーポレイション Treatment of B-cell malignancy using anti-CD20 antibodies and / or anti-CD40L antibodies in combination with chemotherapeutic agents and radiation therapy
CN100490895C (en) 2000-02-01 2009-05-27 泛遗传学公司 APC activating molecule that binds CD40
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
AU2001261585B2 (en) * 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
MXPA03000306A (en) 2000-07-12 2004-04-05 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications.
CA2419841A1 (en) 2000-09-01 2002-03-07 Biogen, Inc. Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003284968A1 (en) 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
WO2005003175A2 (en) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
EP1646654A1 (en) 2003-07-08 2006-04-19 Genesto A/S BINDING MEMBER TOWARDS PNEUMOCOCCUS SURFACE ADHESIN A PROTEIN (PsaA)
EP1653801A4 (en) 2003-07-26 2007-05-30 Biogen Idec Inc MODIFIED ANTIBODIES HAVING IMPROVED ANTIGEN BINDING AFFINITY
JP2007503206A (en) * 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド Improved antibody with altered effector function and method for producing the antibody
US20170166655A1 (en) 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EA013122B1 (en) * 2005-04-06 2010-02-26 Бристол-Маерс Сквибб Компани Methods for treating immune disorders associated with graft transportation with soluble ctla4 mutant molecules
WO2006138316A2 (en) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methods for delivering molecules to the central nervous system
KR100772247B1 (en) 2005-11-04 2007-11-01 엘지전자 주식회사 Chillers for Flat Panel Display Devices and Flat Panel Display Devices
WO2007059332A2 (en) 2005-11-17 2007-05-24 Biogen Idec Ma Inc. Platelet aggregation assays
EP1962886B2 (en) 2005-12-20 2022-02-23 Bristol-Myers Squibb Company Stable protein formulations
US7647438B1 (en) * 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
MX2009010120A (en) * 2007-03-22 2009-10-19 Ucb Pharma Sa Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof.
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CN102119174B (en) 2008-07-17 2015-01-21 诺华股份有限公司 Compositions and methods of use for therapeutic antibodies
GB0815788D0 (en) 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
DK2367849T3 (en) 2008-12-05 2018-01-22 Als Therapy Development Inst METHOD OF TREATING NEURODEGENERATIVE DISEASES
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
US20120100166A1 (en) * 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012103218A1 (en) 2011-01-25 2012-08-02 University Of South Florida A transgenic model of alzheimer's disease
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
US8852597B2 (en) 2011-04-04 2014-10-07 The Trustees Of Dartmouth College Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
MX354243B (en) * 2011-04-21 2018-02-20 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40.
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
TW201817745A (en) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance
SMT202000091T1 (en) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40l
CA2858308A1 (en) 2011-12-08 2013-06-13 Preciflex Sa Low volume precision bellows
DK3207938T3 (en) 2012-05-11 2020-03-16 Medimmune Ltd CTLA-4 VARIANTS
EP2909303B1 (en) 2012-10-18 2020-04-15 Yongxin Zhang Bioreactor system and methods for alternative cell culture between static and dynamic
US11267868B2 (en) * 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
JP6668241B2 (en) * 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド Fc-containing molecules exhibit predictable, consistent and reproducible glycoform properties
AU2015231180B2 (en) * 2014-03-19 2017-06-15 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against CD40L
MX2016013611A (en) 2014-04-25 2017-02-02 Bristol Myers Squibb Co Use of ctla4 compound for achieving drug-free remission in subjects with early ra.
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MA41459A (en) * 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies

Also Published As

Publication number Publication date
KR102747565B1 (en) 2024-12-27
IL253571A0 (en) 2017-09-28
AU2016215505B2 (en) 2021-10-28
GB2552429A (en) 2018-01-24
AU2022200323B2 (en) 2024-07-25
JP2025081304A (en) 2025-05-27
AU2016215505A2 (en) 2019-01-24
SG10201912752QA (en) 2020-02-27
SG11201706258WA (en) 2017-08-30
IL287823A (en) 2022-01-01
US20190092868A1 (en) 2019-03-28
AU2016215505B8 (en) 2021-11-11
NZ733621A (en) 2024-07-05
AU2016215505A1 (en) 2017-07-27
JP2023036717A (en) 2023-03-14
IL253571B (en) 2022-04-01
IL322241A (en) 2025-09-01
US12275793B2 (en) 2025-04-15
KR20170108024A (en) 2017-09-26
GB201713871D0 (en) 2017-10-11
EP4071175A1 (en) 2022-10-12
AU2024204572A1 (en) 2024-09-19
JP2021054826A (en) 2021-04-08
CN108064168B (en) 2021-10-26
EP3253412A1 (en) 2017-12-13
RU2017126997A3 (en) 2019-09-19
RU2727646C2 (en) 2020-07-22
US11692040B2 (en) 2023-07-04
US20170342158A1 (en) 2017-11-30
MX392480B (en) 2025-03-24
EP3253412A4 (en) 2018-08-01
CN114195895B (en) 2024-09-06
WO2016126702A1 (en) 2016-08-11
EP3253412B1 (en) 2022-03-23
CN108064168A (en) 2018-05-22
US11014990B2 (en) 2021-05-25
MX2022005655A (en) 2022-06-29
CA2974135A1 (en) 2016-08-11
US20240043549A1 (en) 2024-02-08
US10106618B2 (en) 2018-10-23
JP6797810B2 (en) 2020-12-09
AU2022200323A1 (en) 2022-02-17
US20200277391A1 (en) 2020-09-03
KR20250007045A (en) 2025-01-13
US20250263493A1 (en) 2025-08-21
DK3253412T3 (en) 2022-05-23
MA41459A (en) 2017-12-12
US10683356B2 (en) 2020-06-16
RU2017126997A (en) 2019-03-04
CN114195895A (en) 2022-03-18
US20210269538A1 (en) 2021-09-02
JP2018510132A (en) 2018-04-12

Similar Documents

Publication Publication Date Title
MX2017009694A (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders.
IL283432A (en) Preparations, methods and systems for the treatment of skin disorders
GT201700081A (en) ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
CL2019001214A1 (en) Pharmaceutical composition, methods for treatment and their uses.
UY35973A (en) ANTIBODY MOLECULES THAT JOIN TIM-3 AND USES OF THE SAME
SI3377637T1 (en) Compositions for use in procedures for the treatment of wounds, disorders and skin diseases
MX2017005258A (en) COMBINED THERAPY FOR TREATMENT OF DISEASE.
EA201790398A1 (en) METHODS OF TREATING LIVER DISEASES
EA201591754A1 (en) HUMAN ANTIBODIES TO NA1.7
PT3481846T (en) 24-HYDROXYSTEROIDS 11-REPLACED FOR USE IN THE TREATMENT OF NMDA-RELATED DISEASES
BR112017016952A2 (en) combination therapy with coagulation factors and multispecific antibodies
EA201691872A1 (en) HETEROCYCLIC COMPOUNDS FOR APPLICATION IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS
CO2017004314A2 (en) Anti-tnf compounds
EP4368228C0 (en) PATIENT INTERFACE SYSTEM FOR THE TREATMENT OF RESPIRATORY DISEASES
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
MX2018008105A (en) METALOENZIMA INHIBITING COMPOUNDS.
MX2015009045A (en) Compositions and methods for treating severe pain.
MX2023006415A (en) ANTIBODIES, USES AND METHODS.
IL264070A (en) Methods and preparations for the treatment of disorders and diseases involving rdh12
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
MA40364A (en) Combination therapy for treatment of cancer
EP3411399A4 (en) SYNERGISTIC DRUG-MEDICINAL SYNERGY TECHNOLOGY FOR THE TREATMENT OF DISEASES
EA201691567A1 (en) METHODS OF TREATING PULMONARY INJURIES TO THE BRAIN
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
BR112019005539A2 (en) Acute Kidney Injury Treatment Methods